このブログへ訪れ頂いた総数2023年12月31日／11：30現在：８６５３５５
2023年年初が：８４０２６１
2023年の訪れて頂いた方の総数２５０９４
びっくりです、訪れ頂き感謝です
来年はどうなるのか、平和産業である、旅行産業はコロナ禍が明けても前途多難、日本国内での旅行はもう完全復活と言っても間違いが無いですが、海外旅行は無理、特に小規模海外専従旅行社の収益の要の企業法人の海外出張は2023年の総括はコロナ禍前2019年の2割〜3割程度の戻り、大手でも5割〜6割くらいの戻りでしょうか
最初は特別軍事作戦と云っていた、識者はまさかロシアがウクライに侵攻するとは、当時は云ってなかったが2022年2月24日にロシアのウクライナ侵攻が始まって今も続いている、2023年10月7日（土）から始まったパレスチナ戦争、心無い海外メディアでは大東亜戦争の日本の真珠湾攻撃になぞらえて報道
そして以下の報道が、
中国の習近平国家主席が11月下旬、軍指揮下の海警局に対し、沖縄県・尖閣諸島について「1ミリたりとも領土は譲らない。釣魚島（尖閣の中国名）の主権を守る闘争を不断に強化しなければならない」と述べ、領有権主張の活動増強を指示したことが30日、分かった。
これを受け海警局が、2024年は毎日必ず尖閣周辺に艦船を派遣し、必要時には日本の漁船に立ち入り検査する計画を策定したことも判明した。
岸田文雄首相が11月中旬の日中首脳会談で習氏に、尖閣を含む東シナ海情勢への「深刻な懸念」を直接伝えたばかり。中国側がこの指摘を顧みず、実際の行動によって領有権主張を強める方針であることが浮き彫りになった。
中国が日本漁船の立ち入り検査計画を策定したことが明らかになるのは初めて。実際に検査を行おうとすれば、海上保安庁の船舶との摩擦拡大は必至で、偶発的な衝突が起きる懸念がさらに高まりそうだ。
習氏は上海で11月29日、海警局の東シナ海海区指揮部を視察した。関係筋によると習氏は尖閣について「前進のみ。引くことはできない」と言明した。
COVID and flu surge could strain hospitals as JN.1 variant grows, CDC warns
/ CBS NEWS
Hospitals and emergency rooms could be forced to ration care by the end of this month, the Centers for Disease Control and Prevention warned Thursday, saying recent trends in COVID-19 and influenza are now on track to again strain America's health care system. The new COVID variant JN.1 is making up an increasing share of cases, the CDC's tracking shows.
"COVID-19 hospitalizations are rising quickly," the agency said in its weekly update. "Since the summer, public health officials have been tracking a rise in multisystem inflammatory syndrome in children (MIS-C), which is caused by COVID-19. Influenza activity is growing in most parts of the country. RSV activity remains high in many areas."
The CDC has been urging people to get vaccinated as the peak of this year's mix of three seasonal respiratory viruses — influenza, COVID-19 and RSV — is nearing.
In pediatric hospitals, the CDC says beds "are already nearly as full as they were this time last year" in some parts of the country. Data from emergency rooms published Wednesday tracked emergency room visits nearly doubling in school-age children last week.
The increase, driven largely by an acceleration in flu cases, follows weeks of largely plateauing emergency room figures nationwide ahead of Thanksgiving.
Similar to this time last year, influenza emergency room visits are now outpacing COVID-19 for the first time in months across most age groups. Only in seniors do rates of COVID-19 remain many times higher than influenza.
Nursing homes have seen a steep rise in reported COVID-19 across recent weeks. In the Midwestern region spanning Illinois, Indiana, Michigan, Minnesota, Ohio and Wisconsin, infections in nursing home residents have already topped rates seen at last year's peak.
Is there a new COVID-19 variant? What to know about JN.1
A new COVID-19 variant called JN.1 has been driving a growing share of the latest wave of infections, officials estimate.
The JN.1 lineage — a closely related descendant of the highly mutated BA.2.86 variant that scientists first warned about over the summer — was estimated last week in the CDC's projections to make up as much as 29% of infections nationwide. That's up from 8.8% at the end of November.
Health officials have been closely tracking the acceleration of BA.2.86 and its descendants, like JN.1, around the world in recent months. More than 4 in 10 test results from the CDC's airport testing program for international travelers have turned up these strains.
A panel of experts convened by the World Health Organization concluded this month that JN.1's changes were not steep enough to warrant a new revision to this season's vaccines, but acknowledgedearly data suggesting these shots were less effective at neutralizing the strain.
"CDC projects that JN.1 will continue to increase as a proportion of SARS-CoV-2 genomic sequences. It is currently the fastest-growing variant in the United States," the CDC said last week.
"Right now, we do not know to what extent JN.1 may be contributing to these increases or possible increases through the rest of December like those seen in previous years," they wrote.
However, so far the CDC had said that so far JN.1's fast spread does not appear to be leading to any upticks in the severity posed by COVID-19.
How big is the vaccination gap?
As COVID-19 and other respiratory viruses have accelerated in recent weeks, health officials say they have also been closely tracking an unprecedented drop in vaccinations this season.
Data from insurance claims suggest flu vaccinations in adults are around 8 million doses behind vaccination levels seen last year. The CDC's survey data suggests flu shots in children are also down around 5 percentage points from the same time last year.
"Covering the missed volume is going to be very difficult or not possible," vaccine manufacturers concluded at a recent stakeholder meeting with the CDC, according to a readout from the National Adult and Influenza Immunization Summit.
Health officials have also been urging providers to redouble their efforts to buoy COVID-19 vaccinations this year, especially for those most at-risk of severe disease like seniors.
In nursing homes, just a third of residents and less than 1 in 10 staff are vaccinated with this season's COVID-19 shot.
"We aren't seeing the uptake in vaccines that we would like to see," CDC Director Dr. Mandy Cohen told doctors at an American Medical Association event Tuesday.
Cohen also cited survey data on uptake of the RSV vaccinations, which were greenlighted for the first time this year in older adults. Around 16% of adults ages 60 and older say they have gotten the shot.
"We acknowledge that is too low and it is one of the reasons we wanted to have this conversation," she said.
冬が本格的に成って来ました、新たな新型コロナの変異株の発症速度が速いですね、それはアメリカで最初の確認されたのが2023年夏の認識ですが、１１月ごろから欧州各国で流行の兆しがとの報道をよく見ますが、
海外旅行には、掛け捨てですが海外旅行保険の加入をお薦めしています、万一旅行先で掛かったならびっくりするくらいの医療費が必要です
Update on SARS-CoV-2 Variant JN.1 Being Tracked by CDC
December 8, 2023,
CDC is posting updates on respiratory viruses every week; for the latest information, please visit CDC Respiratory Virus Updates.
What to know about JN.1
- How variants spread: The virus that causes COVID-19 is constantly changing over time. Sometimes these changes allow new variants to spread more quickly or effectively. If that occurs, the new variant may become more common relative to other variants that are circulating.
- How common: CDC projects that the variant JN.1 comprises an estimated 15–29% of in the United States as of December 8, 2023. More information about these projections, including why JN.1 is appearing on the Nowcast separately for the first time, is available in the section below.
- CDC projects that JN.1 will continue to increase as a proportion of SARS-CoV-2 genomic sequences. It is currently the fastest-growing variant in the United States.
- History: JN.1 is closely related to the variant BA.2.86 that CDC has been tracking since August.
- Even though BA.2.86 and JN.1 sound very different because of the way variants are named, there is only a single change between JN.1 and BA.2.86 in the spike protein.
- JN.1 was first detected in the United States in September 2023. By the end of October, it made up less than 0.1% of SARS-CoV-2 viruses.
- Previously, JN.1 was grouped with BA.2.86 on COVID Data Tracker.
- Impact: The continued growth of JN.1 suggests that it is either more transmissible or better at evading our immune systems. At this time, there is no evidence that JN.1 presents an increased risk to public health relative to other currently circulating variants.
- There is no indication of increased severity from JN.1 at this time.
- Updated COVID-19 vaccines are expected to increase protection against JN.1, as they do for other variants.
- As noted in previous updates, COVID-19 tests and treatments are expected to be effective against JN.1.
- The rapid growth of JN.1 compared with other variants raises the question of whether this variant might drive an incremental increase in infections.
- COVID-19 activity is currently increasing in the United States. We expected this increase because COVID-19 has had a pattern of increasing and peaking in late summer, and then again peaking around the new year.
- Right now, we do not know to what extent JN.1 may be contributing to these increases or possible increases through the rest of December like those seen in previous years. CDC will closely monitor COVID-19 activity and the spread of JN.1.
- Symptoms: It is not currently known whether JN.1 infection produces different symptoms from other variants.
- In general, symptoms of COVID-19 tend to be similar across variants.
- The types of symptoms and how severe they are usually depend more on a person’s immunity and overall health rather than which variant causes the infection.
- What’s next:
- COVID-19 activity is likely to increase over the next month. An updated COVID-19 vaccine can help keep you protected against JN.1 and other variants. It’s a great time to get that vaccine if you haven’t received one this fall.
- Regardless of what variants happen, CDC will continue to track them, working closely with partners around the world to understand how they are spreading and how they respond to vaccines and treatments.
More information for data mavens
- On Dec. 8, 2023, JN.1 is being shown separately for the first time on CDC’s SARS-CoV-2 Nowcast.
- In the most recent weighted estimates, which are directly based on observed genomic sequencing data weighted by geography, JN.1 comprised an estimated 3.5% of U.S. sequences, with a 95% confidence interval (a measure of uncertainty) ranging from 2.4% to 5.0%.
- These data are from the two-week period ending Nov. 11, 2023. See this page for a more detailed explanation of weighted estimates.
- Before this period, JN.1 comprised less than 1% of U.S. sequences.
- CDC makes Nowcast projections for variants that have been at or above this 1% threshold, which is why JN.1 was not shown separately before.
- There are SARS-CoV-2 sequences available for more recent weeks, but using those data can lead to less reliable projections because of differences between which sequences are submitted earlier compared with later. There is an inherent lag in the time it takes to receive specimens for sequencing, do the sequencing, and analyze and report the results.
- CDC analyses have shown that using more complete sequencing data, even if older, provides a more accurate Nowcast than more recent, partial data.
- Early laboratory data suggests that serum from people who received this year’s COVID-19 vaccine block JN.1 viruses from entering cells.
- In CDC’s Nowcast, which forecasts the current situation (i.e., “now”) based on the older, weighted estimates, JN.1 is projected to comprise between 15-29% of currently circulating variants in the United States as of December 8, 2023.
- Currently, our best estimate indicates about 21% of circulating viruses may be JN.1.
- However, early projections tend to be less reliable, since they depend on examining growth trends of a smaller number of sequences. Laboratory-based testing volume for SARS-CoV-2 has decreased substantially over time, and certain geographic regions may be overrepresented. For this reason, this projection may be revised as more data become available in future weeks.
次から次に、旅行へ行く気が阻害される、要因が出てきますね
韓国、インフルエンザ患者５年ぶり最多…パンデミック当時の「免疫負債」が影響
2023年12月16日
インフルエンザ流行が異例にも年中続く中、患者数が５年ぶりの最多となった。
韓国疾病管理庁は１５日、「１２月第２週（３－９日）の外来患者１０００人あたり、インフルエンザが疑われる症状を見せた患者は６１．３人」とし「過去５年間（１９－２３年）で最高水準」と明らかにした。
（中略）
一部の専門家はパンデミック時期の３年間に累積した「免疫負債（ｉｍｍｕｎｅ ｄｅｂｔ）」を返しているとしてこの現象を説明する。強力な防疫措置で新型コロナだけでなく他の呼吸器感染も大幅に減ったが、感染で得る自然免疫力も共に減少し、返すべき負債のように一度に多数が感染するということだ。
トータル
